Sameer Stas is an Endocrinology/Metabolic physician. OpenAlex indexes 13 publications with 1,051 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
123 Newton Sparta Rd
Newton, NJ 078602769
Telephone
973-579-6300Registry record last updated 6 Feb 2017.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insulet CorporationProgram year20256 payments
- Radius Health, Inc.Program year20251 payment
- Abbott LaboratoriesProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.4%Insulin Analog16%Tresiba Flextouch U-20020%Lantus Solostar14%Humalog Kwikpen U-10011%Tresiba Flextouch U-10010%Toujeo Solostar8%Novolog Flexpen7%Basaglar Kwikpen U-1006%Toujeo Max Solostar5%Fiasp Flextouch4%Insulin Lispro Kwikpen U-1003%Levemir Flexpen2%Soliqua 100-332%Humalog Kwikpen U-2002%Lantus2%Humalog2%Insulin Lispro2%Novolog2%Part D<11 patientsGLP-1 receptor agonist11.6%Ozempic51%Trulicity33%Mounjaro14%Rybelsus2%Part D<11 patients+ 11 more classes in this area
Hormonal (systemic)
18.4%l-Thyroxine14.2%Levothyroxine Sodium88%Synthroid10%Levoxyl1%Tirosint1%Part D<11 patientsThyroid Hormone Synthesis Inhibitor2.6%Methimazole100%Part D≥66 patients+ 3 more classes in this area
Musculoskeletal
16.3%RANK Ligand Inhibitor13.8%Denosumab100%Part B, office-administered≥14 patientsBisphosphonates2.4%Risedronate Sodium100%Part D≥68 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”